EQUITY ALERT: The Rosen Law Firm Announces Investigation of Idenix Pharmaceuticals Inc. (IDIX) Concerning the Proposed Acquis...
11 Juin 2014 - 12:12AM
Business Wire
The Rosen Law Firm, P.A. is investigating the Board of Directors
of Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) for possible breaches
of fiduciary duties and other violations of law by failing to
adequately shop Idenix to maximize shareholder value before
entering into an agreement with Merck & Co., Inc.
(NYSE:MRK).
If you would like to join the action, please call Phillip Kim,
Esq. or Kevin Chan, Esq. toll-free, at 866-767-3653; or email at
pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or
obligation to you.
Under the terms of the proposed transaction, shareholders will
receive $24.50 in cash for each share of Idenix stock they own. The
proposed transaction is valued at approximately $3.85 billion. The
investigation relates to whether the proposal is fair to public
shareholders and whether Idenix’s Board of Directors breached its
fiduciary duties in connection with the proposed transaction.
If you own and purchased Idenix common stock before June 9, 2014
and wish to obtain additional information, please visit the website
at http://rosenlegal.com/buyoutcases.html. You may also contact
Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll
free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or
kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
The Rosen Law Firm P.A.Phillip Kim, Esq.Laurence Rosen,
Esq.Kevin Chan, Esq.275 Madison Avenue 34th FloorNew York, New York
10016Tel: (212) 686-1060Toll Free: 1-866-767-3653Fax: (212)
202-3827pkim@rosenlegal.comlrosen@rosenlegal.comkchan@rosenlegal.comwww.rosenlegal.com
(MM) (NASDAQ:IDIX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
(MM) (NASDAQ:IDIX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Idenix Pharmaceuticals, Inc. (MM)